Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 29:18:100641.
doi: 10.1016/j.ajpc.2024.100641. eCollection 2024 Jun.

Lipoprotein(a): Emerging insights and therapeutics

Gurleen Kaur  1 , Khaled Abdelrahman  1 , Adam N Berman  2 , David W Biery  2   3 , Arthur Shiyovich  2 , Daniel Huck  2 , Michael Garshick  4 , Ron Blankstein  2 , Brittany Weber  2
Affiliations

Lipoprotein(a): Emerging insights and therapeutics

Gurleen Kaur et al. Am J Prev Cardiol. .

Abstract

The strong association between lipoprotein (a) [Lp(a)] and atherosclerotic cardiovascular disease has led to considerations of Lp(a) being a potential target for mitigating residual cardiovascular risk. While approximately 20 % of the population has an Lp(a) level greater than 50 mg/dL, there are no currently available pharmacological lipid-lowering therapies that have demonstrated substantial reduction in Lp(a). Novel therapies to lower Lp(a) include antisense oligonucleotides and small-interfering ribonucleic acid molecules and have shown promising results in phase 2 trials. Phase 3 trials are currently underway and will test the causal relationship between Lp(a) and ASCVD and whether lowering Lp(a) reduces cardiovascular outcomes. In this review, we summarize emerging insights related to Lp(a)'s role as a risk-enhancing factor for ASCVD, association with calcific aortic stenosis, effects of existing therapies on Lp(a) levels, and variations amongst patient populations. The evolving therapeutic landscape of emerging therapeutics is further discussed.

Keywords: Atherosclerotic cardiovascular disease; Calcific aortic stenosis; Dyslipidemia; Lipoprotein(a).

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: RB reports consulting/advisory fees from Amgen, and Novartis. MG reports consulting fees from BMS, Aepha, Horizon Therapeutics, Kiniksa Pharmaceuticals Corp. BW reports advisory/consulting from Novo Nordisk, BMS, Aepha, Horizon Therapeutics, and Kiniksa Pharmaceuticals.

Figures

Fig 1
Fig. 1
Summary of emerging Lp(a) therapeutics RNA=ribonucleic acid, mRNA=messenger RNA.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Berman A.N., Blankstein R. Current and future role of Lipoprotein(a) in preventive cardiology. Curr Opin Cardiol. 2019;34(5):514–518. - PubMed
    1. Varvel S., McConnell J.P., Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239–2245. - PubMed
    1. Brandt E.J., et al. Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort. J Clin Lipidol. 2020;14(5):695–706. e4. - PMC - PubMed
    1. Lieb W., et al. Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community. Open Heart. 2018;5(1) - PMC - PubMed
    1. Khera A.V., et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) Circulation. 2014;129(6):635–642. - PMC - PubMed

LinkOut - more resources